

Development of therapeutics for acute myeloid leukemia with CK1alpha selective molecular degrader



ONCOLOGY	Candidate
Product Type	Small molecule molecular glue degrader
Indication	Acute Myeloid Leukemia
Target	CK1 α
MoA(Mechanism of Action)	Cancer cell apoptosis by CK1 α degradation-mediated p53 activation
Competitiveness	<ul style="list-style-type: none"> - Targeting refractory/relapsed patients to approved therapeutics in AML area by degrading a differentiated target protein - Highly selective targeted degradation of CK1alpha - Lower toxicity potential than other similar mechanistic therapeutics
Development Stage	Candidate
Route of Administration	Oral administration or Intravenous administration